- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Molecular phenotyping.
Displaying page 1 of 1.
EudraCT Number: 2011-000924-14 | Sponsor Protocol Number: S52549 | Start Date*: 2011-05-23 |
Sponsor Name:KU Leuven LRD | ||
Full Title: Development and validation of a sputum biomarker mRNA panel for the diagnostic work-up of asthma | ||
Medical condition: asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002738-19 | Sponsor Protocol Number: ESR-17-13092 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: NAsal Polyps: inflammatory & molecular Phenotyping of REsponders to Benralizumab | |||||||||||||
Medical condition: Patients with chronic rhinosinusinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006862-27 | Sponsor Protocol Number: CIK | Start Date*: 2005-05-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Infusion of Cytokine Induced Killer (CIK) cells in patients relapsing after allogeneic stem cell transplantation | |||||||||||||
Medical condition: Patients with hematologic malignancies (excluding CML) with a hematologic or molecular relapse after allogeneic transplantation (at least 60 days should have elapsed since transplant). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000982-30 | Sponsor Protocol Number: 4993/15 | Start Date*: 2016-08-08 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Personalized pharmacological treatment of chronic obstructive pulmonary disease based on phenotyping: interventional study | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002217-59 | Sponsor Protocol Number: 63623872FLZ3002 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, ... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) EE (Completed) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001391-42 | Sponsor Protocol Number: Speed-Covid | Start Date*: 2021-05-12 |
Sponsor Name:Medical University of Graz | ||
Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study | ||
Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-001828-36 | Sponsor Protocol Number: ABP-2019 | Start Date*: 2020-02-21 | |||||||||||
Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||
Full Title: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping | |||||||||||||
Medical condition: Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001141-41 | Sponsor Protocol Number: 08-C-0007 | Start Date*: 2012-09-18 | |||||||||||
Sponsor Name:National Cancer Institute NCI | |||||||||||||
Full Title: A PHASE I STUDY OF IPILIMUMAB (ANTI-CTLA-4) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH TREATMENT REFRACTORY CANCER | |||||||||||||
Medical condition: Sarcoma - Wilm's Tumor - Lymphoma - Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006068-32 | Sponsor Protocol Number: CDX110-04 | Start Date*: 2012-07-04 | |||||||||||
Sponsor Name:Celldex Therapeutics, Inc | |||||||||||||
Full Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma ... | |||||||||||||
Medical condition: Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002156-84 | Sponsor Protocol Number: 63623872FLZ3001 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, a... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000941-10 | Sponsor Protocol Number: CLI24-001 | Start Date*: 2020-07-02 |
Sponsor Name:Menarini Ricerche S.p.A | ||
Full Title: A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia | ||
Medical condition: Acute Myeloid Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-006677-83 | Sponsor Protocol Number: HuLuc63-1703 | Start Date*: 2010-04-26 | |||||||||||
Sponsor Name:AbbVie Biotherapeutics Inc. (AbbVie) | |||||||||||||
Full Title: A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapse... | |||||||||||||
Medical condition: Patients with relapsed multiple myeloma (MM). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
